CG Oncology, Inc. Common stockCGONNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-11.00%
↓ 190% below average
Average (11q)
12.22%
Historical baseline
Range
High:36.58%
Low:-11.00%
Volatility
389.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -11.00% |
| Q2 2025 | 14.07% |
| Q1 2025 | 2.49% |
| Q4 2024 | 36.58% |
| Q3 2024 | 6.24% |
| Q2 2024 | 7.32% |
| Q1 2024 | 8.14% |
| Q4 2023 | 35.62% |
| Q3 2023 | 19.36% |
| Q2 2023 | 25.38% |
| Q1 2023 | 2.40% |
| Q4 2022 | 0.00% |